New effective, field-adapted drug. Together with Bayer Pharma, we are working to develop emodepside as a new treatment for river blindness with the potential to kill both adult filarial worms and their embryonic larvae, which can cause debilitating and disfiguring clinical symptoms.

DNDi and our partners are prioritizing drug development for dengue with a focus on pregnant women, young children, and people with comorbidities. In the short term, we are working to repurpose existing direct-acting antivirals and host-directed therapies. Our aim over the medium term is to develop all-new antivirals.

The first-in-class compound LXE-408 offers new hope to deliver a short-course oral treatment for visceral leishmaniasis. Originally discovered at Novartis, LXE408 is being jointly developed by DNDi and Novartis through a collaboration and licence agreement, with financial support from Wellcome.